Ongoing
Barriers and Facilitators of the “Sex Now 2022” Venue-Based HIV Self-Testing and Peer-Based Linkage to Care Intervention for Sexual Minority Men, Non-Binary, and Two-Spirit People
Learn MoreStart-up
Development and validation of an anal cancer screening algorithm in HIV-positive men who have sex with men
Learn MoreStart-up
A multicenter, randomized controlled trial of the efficacy, safety and immunogenicity of the 9-valent human papillomavirus (HPV) vaccination in preventing recurrence of high-grade anal dysplasia in HIV-positive men who have sex with men (MSM)
Learn MoreOngoing
A randomized controlled, open-label trial examining the efficacy, safety, and tolerability of ablative therapies for high-grade anal dysplasia versus observation alone in HIV-positive men who have sex with men (MSM) – part of HPV-SAVE study.
Learn MoreEnrolling
Development and validation of an anal cancer screening algorithm in HIV-positive men who have sex with men (MSM) – part of HPV-SAVE study.
Learn MoreEnrolling
Optimizing the delivery of HIV post-exposure prophylaxis: A randomized controlled trial of text messaging support and physician to nurse task-shifting
Learn MoreResults
Enrolling
Using a novel assay to detect syphilis infection early in asymptomatic men who have sex with men (MSM) undergoing STI screening
Learn MoreCompleted
Acceptability and implications of the rapid hepatitis C virus screening test among provincial prison inmates in Quebec: A pilot study
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
